Anlotinib Anticancer Drugs Oncology Pharmacology Physiotherapy

Anlotinib (Background-4)

In this article we will discuss Anlotinib (Background-4)

In this article, we will discuss Anlotinib (Background-4). So, let’s get started.

Sunitinib can inhibit VEGFR types 1 and 2 (i.e., FLT1 and FLK1/KDR, respectively), PDGFR-α, PDGFR-β, the stem cell factor receptor c-KIT, as well as FLT3 and RET kinases. In patients with renal cell carcinoma (RCC), sorafenib can significantly improve progression-free survival (PFS) from 2.8 to 5.6 months compared to that of placebo and sunitinib can increase PFS from 5.0 to 11.0 months compared to that of interferon (IFN).

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.